Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

SEE ID, Inc., doing business as Dot Ai ("Dot Ai" or "the Company"), a pioneering startup at the forefront of asset intelligence technology, announced today it has hired Toni Buhrke as Vice President ...

Bernstein analyst Miki Sogi maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) yesterday and set a price target ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

A health ministry panel of experts on July 31 endorsed the plan for Daiichi Sankyo Co. to begin producing and distributing the vaccine, which creates immunity for the conventional strain of the virus.

Some are leveraging Merck's partnership with Daiichi ... Sankyo to develop antibody drug conjugates ("ADCs"), a pioneering new type of dual action therapy (two candidates to date - ifinatamab ...

For example, AstraZeneca and Daiichi Sankyo have shown how AI spatial scoring can help identify breast cancer patients who positively responded to HER2-directed ADC trastuzumab deruxtecan ...

Other agents that have been evaluated in recurrent/advanced endometrial cancer in the post-platinum setting include bevacizumab, letrozole plus everolimus, trastuzumab deruxtecan (for HER2+ cancer ...

patients eligible for treatment with Daiichi Sankyo’s Enhertu (fam-trastuzumab deruxtecan-nxki).

Trastuzumab deruxtecan (T-DXd) continued to show benefit in the updated data from the DESTINY-Breast03 trial (NCT03529110). Special attention should be paid to the toxicities of nausea and pneumonitis ...